Get the Stockscreener App
54.09
0.20%
-0.11
After Hours:
54.19
0.10
+0.18%
Akero Therapeutics Inc stock is traded at $54.09, with a volume of 1.44M.
It is down -0.20% in the last 24 hours and up +17.33% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.20
Open:
$54.11
24h Volume:
1.44M
Relative Volume:
0.70
Market Cap:
$4.33B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-14.42
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+0.45%
1M Performance:
+17.33%
6M Performance:
+20.55%
1Y Performance:
+67.31%
1-Day Range:
$54.00
$54.20
1-Week Range:
$53.74
$54.31
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.09 | 4.34B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
How high can Akero Therapeutics Inc. stock goEarnings Trend Report & Daily Growth Stock Tips - newser.com
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
Heatmap analysis for Akero Therapeutics Inc. and competitorsJuly 2025 Patterns & Community Supported Trade Ideas - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunity - newser.com
Can Akero Therapeutics Inc. (0K4) stock beat analyst consensusJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economyTrade Analysis Report & Real-Time Volume Surge Alerts - newser.com
Is Akero Therapeutics Inc. stock a buy before product launchesWeekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Will Akero Therapeutics Inc. stock gain from lower inflationTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
Can volume confirm reversal in Akero Therapeutics Inc.GDP Growth & Safe Entry Trade Reports - newser.com
How rising interest rates impact Akero Therapeutics Inc. stockCEO Change & AI Driven Price Predictions - newser.com
Can Akero Therapeutics Inc. (0K4) stock surprise with quarterly resultsWeekly Loss Report & Community Driven Trade Alerts - newser.com
Will Akero Therapeutics Inc. outperform the marketGap Down & Comprehensive Market Scan Insights - newser.com
Why Akero Therapeutics Stock Trounced the Market on Thursday - AOL.com
Using RSI to spot recovery in Akero Therapeutics Inc.Gap Up & Expert Curated Trade Setups - newser.com
Chart based analysis of Akero Therapeutics Inc. trendsWeekly Market Outlook & Entry Point Confirmation Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonPortfolio Risk Summary & Technical Entry and Exit Alerts - newser.com
Jennison Associates LLC Grows Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. stock reach Wall Street targetsAnalyst Downgrade & High Conviction Buy Zone Alerts - newser.com
Y Intercept Hong Kong Ltd Takes Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat
Fatty liver disease companies' multibillion-dollar deals mean fatter walletsSan Francisco Business Times - The Business Journals
Is Akero Therapeutics Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly High Return Opportunities - newser.com
Emerald Mutual Fund Advisers Trust Has $7.27 Million Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Is Akero Therapeutics Inc. (0K4) stock included in top ETFsJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):